BioLine RX News

News

Ticker

BLRX.TA

ISIN

IL0011015182

Omzet Winst K/W-verhouding P/S EBIT Dividend Insiertransacties Aandelen Marktkapitalisatie Schuld Verplichtingen Eigen vermogen AAQS Medewerkers ROE ROA ROCE News Documenten

BioLine RX Eulerpool Nieuws

BioLine RX Aandeel Nieuws

BioLine RX wordt door journalisten en beleggers ter wereld gevolgd. De laatste BioLine RX nieuws stellen wij hier samen.

20 maart·
Benzinga
Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings
26 februari·
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
23 februari·
Benzinga
Arbitrator Issues Final Award To BioLineRx, Denies All Claims By Biokine Therapeutics; Biokine To Pay Expenses And Legal Fees
29 november·
Yahoo
BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
25 november·
Yahoo
BLRX: Stem Cell Mobilization Presentation at ASH
24 november·
Yahoo
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
24 november·
SeekingAlpha
BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript
18 november·
Yahoo
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
17 november·
Yahoo
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
30 september·
Yahoo
BLRX: A Venture into GBM
29 september·
SeekingAlpha
BioLineRx Ltd. (BLRX) Investor Call (Transcript)
29 september·
SeekingAlpha
BioLineRx Ltd. - Special Call
14 augustus·
SeekingAlpha
BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript
14 augustus·
Benzinga
Earnings Scheduled For August 14, 2025
3 juli·
Yahoo
H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025
17 juni·
Benzinga
Where BioLine Rx Stands With Analysts
9 juni·
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
31 mei·
Yahoo
BioLineRx upgraded to Buy from Hold at JonesResearch
30 mei·
Benzinga
Dow Edges Higher; Dell Shares Fall After Q1 Results
30 mei·
Yahoo
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

BioLine RX Aandeel Persberichten

BioLine RX publiceert op de bedrijfswebsite regelmatig mededelingen die voor beleggers relevant zijn.

18 november•
BioLine RX
Biolinerx Reports Third Quarter 2021 Financial Results And Provides Corporate Update
18 augustus•
BioLine RX
BioLine RX Reports Q2 Loss Per Share Of $0.01
26 mei•
BioLine RX
Biolinerx Reports Q1 2021 Financial Results
4 mei•
BioLine RX
Biolinerx Announces Positive Top-Line Results From Genesis Phase 3 Trial Of Motixafortide In Stem-Cell Mobilization For Autologous Bone Marrow Transplantation In Multiple Myeloma Patients
23 februari•
BioLine RX
Biolinerx Reports Year-End 2020 Financial Results
19 januari•
BioLine RX
Biolinerx Announces $10 Million Bought Deal Offering
16 december•
BioLine RX
Biolinerx Announces Final Results From Phase 2A Combat/Keynote-202 Triple Combination Study Of Motixafortide
23 november•
BioLine RX
BioLineRx Reports Q3 Loss Per Share $0.02
18 november•
BioLine RX
BiolineRx Announces Initiation Of Phase 1B Clinical Trial In Patients With Acute Respiratory Distress Syndrome Secondary To COVID-19 And Other Respiratory Viral Infections
30 oktober•
BioLine RX
Biolinerx Announces Positive Results From Interim Analysis Of Genesis Phase 3 Trial Of Motixafortide In Stem Cell Mobilization
6 augustus•
BioLine RX
BioLineRx Says On Track To Report Three Significant Data Readouts In Next Few Months
20 mei•
BioLine RX
Bioline Rx Ltd Reports Q1 Loss Per Share Of $0.04
12 maart•
BioLine RX
Bioline On Track To Report Data From Triple Combination Arm Of Ongoing Mid-stage Trial In Mid-2020

BioLine RX News 2026

Deze pagina bevat al het huidige nieuws, analyses en persberichten voor BioLine RX aandelen (BLRX.TA, ISIN: IL0011015182). Dit omvat Eulerpool-nieuws, bedrijfsanalyses en officiële persberichten. Gegevens worden regelmatig bijgewerkt om beleggers een volledig overzicht van de nieuwste ontwikkelingen bij BioLine RX te bieden.

BioLine RX Aandeel

BioLine RX BioLine RX Ltd is een wereldwijd biopharmaceutisch bedrijf dat zich specialiseert in de ontwikkeling van nieuwe therapieën voor kanker en andere ernstige ziekten. Het bedrijf heeft zijn hoofdkantoor in Israël en kantoren in de Verenigde Staten en Europa.